RFDA - ETF AI Analysis
Top Page
RiverFront Dynamic US Dividend Advantage ETF (RFDA)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and over the past few months, showing positive momentum.
Well-Known, Strong Top Holdings
Many of the largest positions, such as UnitedHealth, Johnson & Johnson, Nvidia, and Alphabet, have shown strong or steady performance, helping support the fund’s returns.
Broad Sector Diversification
Holdings are spread across many sectors, including financials, health care, technology, energy, and others, which helps reduce the impact if one industry struggles.
Negative Factors
Higher Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of your returns go toward fees each year.
Heavy U.S. Concentration
With almost all assets in U.S. companies, the ETF offers little geographic diversification and is highly tied to the U.S. economy.
Mixed Performance Among Top Tech Names
While some technology holdings like Nvidia have done well, others such as Microsoft have shown weaker recent performance, which can create uneven results within the portfolio.
RFDA vs. SPDR S&P 500 ETF (SPY)
AUM87.86M
RegionNorth America
Expense Ratio0.52%
Beta0.87
IssuerALPS
Inception DateJun 06, 2016
Dividend Yield1.79%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,617
30 Day Avg. Volume2,006
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
80.49Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering78
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RFDA Summary
RFDA is the RiverFront Dynamic US Dividend Advantage ETF, focused on the overall U.S. stock market with an emphasis on companies that pay dividends. It doesn’t track a fixed index, but instead actively shifts its holdings across many sectors like financials, health care, and technology. Well-known companies in the fund include Microsoft, Apple, UnitedHealth, and JPMorgan Chase. An investor might choose RFDA for a mix of growth potential and regular dividend income in one diversified investment. A key risk is that its stock holdings can rise or fall with the broader U.S. market, and active management decisions may not always perform well.
How much will it cost me?The RiverFront Dynamic US Dividend Advantage ETF (RFDA) has an expense ratio of 0.52%, meaning you’ll pay $5.20 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, which involves more frequent adjustments to the portfolio to respond to market trends. Active management typically comes with higher costs compared to passively managed funds that track an index.
What would affect this ETF?The RiverFront Dynamic US Dividend Advantage ETF (RFDA) could benefit from growth in the technology sector, which makes up a significant portion of its holdings, especially with companies like Nvidia, Microsoft, and Apple driving innovation. However, rising interest rates or economic slowdowns could negatively impact dividend-paying stocks and sectors like financials and consumer cyclical, which are also key components of the ETF. Additionally, regulatory changes affecting large-cap tech companies may pose risks to its top holdings.
RFDA Top 10 Holdings
RFDA leans into U.S. dividend payers, with big banks and industrial and tech names steering returns. Financials like Citigroup and JPMorgan are doing the heavy lifting, with both stocks rising and helping the fund’s income story. UnitedHealth and Caterpillar are also powering ahead, giving a boost from health care and industrials. On the tech side, Nvidia and TSMC are still important growth engines, though Nvidia’s momentum looks a bit mixed lately, while IBM is losing steam. Overall, it’s a U.S.-centric, dividend-focused mix with a noticeable tilt toward financials and mature tech.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Johnson & Johnson | 3.18% | $2.78M | $615.36B | 52.91% | 78 Outperform | |
| UnitedHealth | 3.13% | $2.74M | $391.69B | 52.04% | 72 Outperform | |
| JPMorgan Chase | 3.10% | $2.71M | $933.03B | 17.99% | 72 Outperform | |
| Nvidia | 2.65% | $2.32M | $5.13T | 20.16% | 76 Outperform | |
| Citigroup | 2.63% | $2.30M | $226.80B | 38.25% | 68 Neutral | |
| Conocophillips | 2.31% | $2.02M | $144.72B | 25.70% | 78 Outperform | |
| Phillips 66 | 2.04% | $1.79M | $84.76B | 66.49% | 73 Outperform | |
| Apple | 1.98% | $1.74M | $4.79T | 50.48% | 79 Outperform | |
| Microsoft | 1.97% | $1.72M | $2.90T | -25.31% | 79 Outperform | |
| Exxon Mobil | 1.96% | $1.71M | $640.11B | 41.61% | 74 Outperform |
RFDA Technical Analysis
Positive
―
Price Trends
70.12
Positive
67.36
Positive
65.09
Positive
Market Momentum
0.41
Positive
56.32
Neutral
76.04
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RFDA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 70.98, equal to the 50-day MA of 70.12, and equal to the 200-day MA of 65.09, indicating a bullish trend. The MACD of 0.41 indicates Positive momentum. The RSI at 56.32 is Neutral, neither overbought nor oversold. The STOCH value of 76.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RFDA.
RFDA Peer Comparison
Comparison Results
Performance Comparison
RFDA
RiverFront Dynamic US Dividend Advantage ETF
71.30
12.94
22.17%
BAMD
Brookstone Dividend Stock ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
YALL
God Bless America ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents